Dab tsi yog kev siv 99% ntshiab erdafitinib hmoov?

1. Taw qhia

Erdafitinib hmoov 99%purity muaj cov tshuaj formula C₂₅H₃₀N₆O₂ thiab molecular hnyav ntawm 446.56; nws molecular scaffold suav nrog cov qauv heterocyclic xws li lub nplhaib quinoxaline, ib lub nplhaib pyrazole, thiab ib pawg dimethoxyphenyl, uas yog cov khoom siv me me tsom rau cov khoom siv raw thiab raug cais raws li lub lauj kaub FGFR tyrosine kinase inhibitor. Erdafitinib hmoov 99%, nrog nws cov qauv molecular tshwj xeeb, tuaj yeem tsom FGFR tsev neeg receptors thiab thaiv qhov txawv txav ntawm cov qog ua haujlwm, ua rau nws siv cov ntaub ntawv tshawb fawb hauv kev tiv thaiv -cov tshuaj tsim kho qog noj ntshav.

Hauv kev hla -b ciam teb B2B kev yuav khoom, cov kws paub txog tshuaj R&D cov neeg yuav khoom tsis nug seb Erdafitinib siv tshuaj tiv thaiv- qog nqaij hlav. Lawv nug seb qhov purity specification, tus qauv impurity, thiab qhov twg batch stability profile yuav tsis tu ncua xa cov txiaj ntsig raug thiab rov ua dua tshiab hauv kev sim tshuaj preclinical thiab cov phiaj xwm tsim tshuaj. Formulators nrhiav tau siab -purity Erdafitinib hmoov 99% rau FGFR txoj kev tshawb fawb, cov ntaub ntawv pov thawj ntawm cov tshuaj pharmacodynamic, thiab cov phiaj xwm kev tsim tshuaj yuav tsum tau saib dhau lub hom phiaj inhibition kev ua tau zoo thiab tsom mus rau cov ntsiab lus tseem ceeb uas txiav txim siab qhov kev sim siab thiab kev siv tshuaj nyob rau hauv cov kev sim ntawm tes, tsiaj qauv thiab cov ntaub ntawv preclinical dosage.

Lub ntiaj teb no Erdafitinib hmoov API lag luam tau txuas ntxiv nws txoj kev nthuav dav mus txog 2026,tsav los ntawm peb lub zog sib koom ua ke: qhov kev kho mob ntau ntxiv ntawm FGFR- cov qog nqaij hlav hloov nrog rau urothelial carcinoma thiab cholangiocarcinoma, booming thoob ntiaj teb kev thov rau lauj kaub -FGFR tsom inhibitor kev tshawb fawb thiab kev tsim tshuaj tshiab, thiab kev lag luam loj hlob tsom mus rau cov qog tshuaj tiv thaiv kab mob kev tshawb nrhiav thiab kev sib xyaw ua ke kho kom zoo. 99% siab-purity hmoov daim ntawv tseem yog cov ntaub ntawv muaj ntau yam thiab muaj ntaub ntawv pov thawj raw cov ntaub ntawv, ua tau zoo nrog rau hauv vitro cell assays, hauv vivo tsiaj qauv kev tswj hwm, preclinical formulation screening, pharmacokinetic testing thiab kws tshuaj ntsuam xyuas scale - nce kev tshawb fawb.

Ntawm Xi'an Faithful BioTech Co., Ltd., peb siv cov cuab yeej siv siab heev thiab cov txheej txheem tsim khoom los muab siab - zooErdafitinibnrog purity txog li 99%, tag nrho ua raws li thoob ntiaj teb cov qauv tshuaj. Peb nquag pab cov neeg siv khoom los ntawm thoob ntiaj teb platforms xws liAlibaba.com; peb cov nqi sib tw thiab kev pabcuam zoo heev tau ua rau peb xaiv ntau yam, thiab koj tuaj yeem xaiv peb nrog kev ntseeg siab.

2.Molecular mechanisms hauv qab cov yam ntxwv ntawm erdafitinib

Erdafitinib hmoov 99% yog lub hwj chim, qhov ncauj bioavailable lauj kaub -FGFR tyrosine kinase inhibitor, thiab nws cov cim molecular tshwm sim los ntawm kev cuam tshuam tshwj xeeb ntawm nws cov qauv tshuaj thiab FGFR tsev neeg kinases. Tsis zoo li FGFR- xaiv inhibitors uas tsuas yog tsom rau ib qho subtype, erdafitinib tuaj yeem khi nruj rau FGFR1, FGFR2, FGFR3 thiab FGFR4 ib txhij, uas tsim lub hauv paus molecular ntawm nws lub lauj kaub -FGFR kev ua. Cov molecule nyob hauv ATP-binding hnab tshos nyob rau hauv lub kinase domain ntawm FGFR receptors, sib tw nrog endogenous ATP los thaiv receptor phosphorylation. Yog tsis muaj phosphorylation, downstream signaling cascades xws li RAS/MAPK thiab PI3K/AKT tsis tuaj yeem qhib tau, yog li txwv tsis pub qog cell proliferation, ntxeem tau thiab tiv thaiv -apoptosis ciaj sia taus los ntawm mutated FGFR.

Tus qauv tsim ntawm erdafitinib kuj piav qhia nws qhov kev nkag siab zoo rau FGFR kev hloov pauv. Ntau cov qog nqaij hlav muaj cov kev hloov pauv ntawm FGFR, cov noob fusions lossis kev nthuav dav uas kaw FGFR nyob rau hauv lub xeev ua haujlwm. Erdafitinib hmoov 99% heterocyclic scaffold fits zoo rau hauv cov hloov pauv kinase hnab tshos ntawm cov mutant receptors, tuav ruaj khov affinity thaum uas qhia tsis muaj zog inhibition rau cov tsiaj qus- hom FGFR nyob rau hauv ib txwm cov ntaub so ntswg. Cov cuab yeej no muab cov kev xaiv los tiv thaiv- qog ua haujlwm thiab txo qhov tsis yog -cytotoxicity tshwj xeeb piv nrog cov tshuaj siv tshuaj kho mob.

Ib qho zoo - paub tus yam ntxwv ntawm erdafitinib yog nws lub peev xwm los cuam tshuam phosphate homeostasis. FGFR signaling yog qhov tseem ceeb rau lub raum phosphate excretion. Thaum erdafitinib suppresses FGFR kev ua haujlwm hauv lub raum tubular hlwb, phosphate reabsorption nce thiab cov ntshav phosphate nce. Qhov no ntawm - lub hom phiaj pharmacologic nyhuv yog biomarker paub tseeb tias muaj kev vam meej FGFR inhibition, es tsis yog tawm - cov tshuaj tiv thaiv tshuaj lom.

Erdafitinibmuaj cov tshuaj tiv thaiv me me tawm tsam ntau lwm kinases xws li RET, PDGFRA thiab KIT. Cov tsis muaj zog tawm ntawm no -cov phiaj xwm sib cuam tshuam ua rau nws qhov dav dav ntawm cov kab mob lom neeg tab sis kuj yog ib feem ntawm cov xwm txheej tsis zoo uas tau pom nyob rau hauv qhov chaw kho mob thiab chaw kho mob. Tsis tas li ntawd, cov qog nqaij hlav tuaj yeem tsim cov kev hloov pauv FGFR thib ob lossis ua kom dhau los ntawm kev taw qhia txoj hauv kev tom qab raug erdafitinib, uas sawv cev rau cov tub ntxhais molecular mechanism ntawm kev tiv thaiv.

Hauv cov ntsiab lus, qhov txawv ntawm erdafitinib yog txiav txim siab los ntawm nws txoj kev khi rau FGFR kinase domains, broad subtype coverage, mutation preference, on -target phosphate metabolism interference and limit off-target kinase inhibition. Cov txheej txheem molecular no txhais nws cov kev ua haujlwm pharmacological, lub qhov rais kho mob, cov lus teb biomarker thiab cov qauv ua haujlwm hauv FGFR- hloov cov qog nqaij hlav.

3.Mechanism of Action of Erdafitinib

Erdafitinib hmoov 99%, me me -molecule targeted inhibitor uas ua ncaj qha rau hauv cov cellular FGFR proteins. Ua raws li kev hloov pauv caj ces tshwj xeeb, FGFR cov proteins txuas ntxiv tso tawm cov cim kev loj hlob, ua rau tsis muaj kev tswj hwm kev loj hlob thiab nthuav dav ntawm cov hlwb. Erdafitinib thaiv cov teeb liab txoj hauv kev los ntawm kev khi rau qhov chaw nquag ntawm FGFR protein. Thaum qhov kev nthuav qhia kev nthuav dav no cuam tshuam, cov hlwb txawv txav tsis tau txais cov lus qhia txuas ntxiv mus ntxiv, ua rau muaj kev cuam tshuam loj hauv lawv qhov kev loj hlob. Tsis tas li ntawd, erdafitinib inhibits FGFR protein phosphorylation, yog li attenuating downstream signaling thiab txo cov kev muaj peev xwm ntawm cov hlwb txawv txav. Qhov kev txiav txim no yog qhov kev xaiv zoo heev, tshwj xeeb tshaj yog cuam tshuam rau cov hlwb harboring FGFR genetic alterations thaum txo kev cuam tshuam nrog cov hlwb ib txwm.

4.Kev siv ntawm Erdafitinib Powder 99%

1. API R&D: Siv hauv kev tsim kho los tsim cov ntsiav tshuaj ntawm qhov ncauj rau kev kho mob hauv zos qib siab lossis metastatic urothelial carcinoma harboring FGFR genetic alterations.
2. Kev Tshawb Fawb Txog Kev Tshawb Fawb: Siv los ua cov khoom siv raw rau ntawm tes-raws li thiab * hauv vitro* kev soj ntsuam los tshawb xyuas cov cwj pwm lom neeg cuam tshuam nrog FGFR txoj hauv kev.
3. Cov ntaub ntawv siv rau Kev Txhim Kho Cov Tshuaj Siv Tshuaj: Ua haujlwm siab -cov qauv siv purity rau kev kuaj muaj zog, kev tshuaj xyuas impurity, thiab cov qauv siv tau.
4. Expanded Oncology Development: Siv los tshawb txog lub peev xwm los kho lwm cov qog nqaij hlav uas cuam tshuam nrog kev hloov pauv FGFR.

5.Kev siv 99% Erdafitinib hmoov hauv cov khoom tiav

Erdafitinib hmoov 99%feem ntau yog siv nyob rau hauv thaum ntxov- theem kev txhim kho ntawm cov hom phiaj kho mob qog noj ntshav, ua haujlwm rau cov chaw tshawb fawb thiab cov tuam txhab tshuaj hauv kev tsim cov qauv tsim rau cov qog nqaij hlav. Txoj kev loj hlob ntawm cov tshuaj tsom rau FGFR- cov qog hloov pauv sawv cev rau qhov tseem ceeb rau cov khoom siv raw no; cov ntaub ntawv kev lag luam qhia tau hais tias qhov kev thov nce ntxiv rau cov kev kho mob zoo li no, nrog ntau lub tuam txhab tshuaj tshawb nrhiav kev txhim kho ntxiv nyob rau ntau hom qog nqaij hlav.

Thov xav txog cov ntsiab lus hauv qab no thaum yuav khoom:

1. Thov HPLC (High -Performance Liquid Chromatography) cov ntaub ntawv tshwj xeeb rau isomers, es tsis yog tag nrho cov ntsiab lus ntawm Erdafitinib.
2. Ua ntej muab cov nqi sib piv, paub meej tias cov khoom xa tuaj yog qhov koj xav tau daim ntawv noj tshuaj zaum kawg.
3. Thov kom ceev cov ntaub ntawv ruaj ntseg rau cov khoom tshwj xeeb uas koj npaj siab yuav.
4. Txheeb xyuas tus neeg muag khoom qhov tshwj xeeb hais txog Erdafitinib cov ntsiab lus thiab kev huv huv kom ntseeg tau tias cov khoom sib xws koj xav tau.
5. Khaws Erdafitinib hmoov rau hauv lub thawv ntim ntawm -20 degree, tiv thaiv los ntawm lub teeb.

6.Cov lus nug cov neeg yuav khoom nug ua ntej muab qhov kev txiav txim ntau

Q1: Puas tuaj yeem loj - cov khoom tsim tawm tsis tu ncua khaws 99% purity? Puas yog daim ntawv tshaj tawm COA suav nrog txhua pawg?

A1: Kev tsim khoom loj tsis tu ncua ua tiav ntau dua lossis sib npaug rau 99% purity; ib daim ntawv pov thawj ntawm COA (Certificate of Analysis) hauv Suav thiab Askiv yog muab rau txhua qhov kev xa khoom, suav nrog cov ntaub ntawv tiav ntawm impurities, cov ntsiab lus noo noo, thiab cov hlau hnyav.

Q2: Lub ntim rau 99% Erdafitinib hmoov yog dab tsi, thiab dab tsi yog cov xwm txheej rau lub sijhawm ntev - khaws cia?

A2: Nqus- ntim cov ntawv ntim aluminium; yuav tsum khaws cia ntawm -20 degree, kaw thiab tiv thaiv los ntawm lub teeb; Cov khoom xa tuaj ntau yog thauj khoom siv cov khoom ntim qis qis.

Q3: Dab tsi yog qhov ntau lawm thiab xa khoom lub sij hawm rau loj - ntim xaj? Puas yog cov khoom hauv Tshuag?

A3: Cov khoom lag luam txheem muaj rau kev xa khoom sai; Kev txiav txim loj heev yuav tsum tau teem sijhawm ntau lawm, thiab hnub xa tuaj tuaj yeem lees paub ua ntej.

7. Cov lus xaus

Erdafitinib hmoov 99% purity yog ib qho tshuaj nquag siv (API) ua lub lauj kaub -FGFR inhibitor. Vim nws lub peev xwm pharmacological rau ib txhij inhibit tag nrho plaub FGFR subtypes, nws tau dhau los ua cov ntaub ntawv tseem ceeb hauv kev tshawb fawb thiab kev tsim kho kev kho mob rau FGFR-mutated cov qog nqaij hlav. Los ntawm kev thaiv txoj kev FGFR kev taw qhia thiab inhibiting kev loj hlob thiab kev cuam tshuam ntawm cov qog hlwb harboring cuam tshuam kev hloov pauv, Erdafitinib hmoov (99%) yog siv rau hauv txoj kev tshawb nrhiav txoj hauv kev, kev tsim tshuaj -cov qauv kev tiv thaiv, thiab kev txhim kho ntawm qhov ncauj formulations.

Xi'an Faithful BioTech Co., Ltd.siv cov cuab yeej siv siab heev thiab cov txheej txheem los xyuas kom meej - cov khoom zoo. Peb Erdafitinib hmoov 99% ua tau raws li cov qauv tshuaj thoob ntiaj teb. Peb txoj kev nrhiav kev ua tau zoo, tus nqi tsim nyog, thiab cov kev pabcuam zoo tshaj plaws ua rau peb yog tus khub rau cov tsev kho mob thiab cov kws tshawb fawb thoob ntiaj teb.

Yog tias koj xav tau Erdafitinib hmoov 99% kev tshawb fawb lossis kev tsim khoom

Thov hu rau peb Nyem

Email:allen@faithfulbio.com 

WhatsApp pawg:+86 13137770562.

8. Cov ntaub ntawv

1. Perera TPS, Jovcheva E, Mevellec L, et al. Discovery thiab pharmacological yam ntxwv ntawm JNJ-42756493 (erdafitinib), ib tug functionally selective me-molecule FGFR tsev neeg inhibitor. Molecular Cancer Therapeutics, 2017,16(6):1010-1020.
2. Karkera JD, Cardona GM, Bell K, et al. Oncogenic characterization thiab pharmacologic rhiab heev ntawm activating fibroblast kev loj hlob yam receptor genetic alterations rau cov xaiv FGFR inhibitor erdafitinib. Molecular Cancer Therapeutics, 2017,16(8):1717-1726.
3. Pant S, Schuler M, Iyer G, et al. Erdafitinib hauv cov neeg mob uas muaj cov qog nqaij hlav loj heev nrog FGFR alterations (RAGNAR): ib qho kev kawm thoob ntiaj teb, ib leeg - caj npab, theem 2 kev kawm. Lub Lancet Oncology, 2023, 24(8): 925-935.
4. Loriot Y, Clément JM, de Santis M, et al. Erdafitinib piv rau cov kws khomob hauv metastatic urothelial carcinoma nrog FGFR hloov pauv. Phau ntawv Journal of Clinical Oncology, 2023, 41(17): 1962-1972.
5. Xiao JF, Caliri AW, Duex JE, Theodorescu D. Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling. Cancer, 2021,13(19):4891.
6. BALVERSA Cov Lus Qhia. Horsham, PA: Janssen Biotech, Inc.
7. Leslie SW, Soon-Sutton TL, Aeddula NR. Bladder Cancer. StatPearls, 2025.